Intellia Therapeutics

YTD

ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

403

Employees403

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

403

Employees403

NTLA Key Statistics

Market cap

847.29M

Market cap847.29M

Price-Earnings ratio

-1.56

Price-Earnings ratio-1.56

Dividend yield

—

Dividend yield—

Average volume

2.85M

Average volume2.85M

High today

$8.30

High today$8.30

Low today

$8.00

Low today$8.00

Open price

$8.08

Open price$8.08

Volume

1.53M

Volume1.53M

52 Week high

$28.18

52 Week high$28.18

52 Week low

$5.90

52 Week low$5.90

NTLA News

TipRanks 4d

Intellia Therapeutics upgraded at Wolfe on sentiment, valuation

As previously reported, Wolfe Research analyst Andy Chen upgraded Intellia Therapeutics (NTLA) to Outperform from Peer Perform with a $21 price target With ente...

Analyst ratings

75%

of 28 ratings

Buy

75%

Hold

21.4%

Sell

3.6%